Proposal of New Imaging Criteria for Evaluating the Response of Liver Metastases to Systemic Treatments in Digestive Neuroendocrine Tumors (NET) as an Alternative to RECIST 1.1 Abstract #2993

Introduction: RECIST 1.1 criteria have been challenged for the evaluation of treatment response in NET.
Aim(s): To explore alternative computed tomography (CT) response evaluation criteria in metastatic NET.
Materials and methods: We included patients with small-intestine (n=50) or pancreatic (n=54) well-differentiated NET with liver metastases (LM), who received systemic therapy as first two treatment lines in 14 expert centers. Baseline (+/- 1 month) and first reevaluation (within 6 months) contrast-enhanced CT scans were locally reviewed to measure LM diameter (5 LM) and density (arterial and portal phases, 2 LM). Multivariate Cox regression analyses explored which response criteria best correlated with progression-free survival (PFS), considering different thresholds of size or density decrease (10%, 20% or 30%) and number of measured LM (2, 3 or 5).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: Dr Louis de Mestier

To read results and conclusion, please login ...

Further abstracts you may be interested in

#29 Serum chromogranin A correlation with tumor burden in metastatic small bowel carcinoid patients
Introduction: Patients with neuroendocrine tumors may have clinical courses that range from fairly indolent to more aggressive. Cross–sectional studies, nuclear imaging and biochemical markers are often used to monitor disease progression. Optimal surveillance tests and intervals have not been firmly established. Studies suggest that chromogranin A (CgA) may be a surrogate marker for tumor burden.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Mr. Thomas Curran
#642 Correlation Between Chromogranin A and RECIST in Neuroendocrine Tumors’ Treatment
Introduction: High Chromogranin A (CGA) levels have been associated with both tumor burden and the secretory activity of GEPNETs specially carcinoids.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Biomarkers
Presenting Author: PhD MD Paula Jimenez Fonseca
#667 Comparison of Response Evaluation in Patients with Gastroenteropancreatic and Thoracic Neuroendocrine Tumors after Treatment with [177Lu-DOTA0,Tyr3]Octreotate
Introduction: Response Evaluation Criteria in Solid Tumors (RECIST) (unidimensional), Southwest Oncology Group (SWOG) solid tumor response criteria (bidimensional), and their modified variants (mRECIST/mSWOG) are used to assess treatment response in gastroenteropancreatic and thoracic neuroendocrine tumors (NETs).
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Esther I Van Vliet
#772 Role of Molecular Imaging using Ga-68 Somatostatin-Receptor PET/CT in Predicting Survival after Peptide Receptor Radionuclide Therapy of Neuroendocrine Neoplasms
Introduction: Peptide receptor radionuclide therapy (PRRNT) is valuable for the management of metastasized and/or inoperable neuroendocrine neoplasms (NENs).
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Dr. Harshad Kulkarni
#1079 CT Imaging Findings of Gastric Neuroendocrine Neoplasm According to 2010 WHO Classification
Introduction: Gastric neuroendocrine neoplasm(G-NEN) is rarely detected at an early stage. Its prognosis varies based on grade and stage.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: ZH W Liang
Authors: Jiang L M, Liang Z W, Li Y, Geng C Y, ...